<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective effect of YM872 ([2.3-dioxo-7-(<z:chebi fb="0" ids="50053">1H-imidazol-1-yl</z:chebi>) 6-<z:chebi fb="13" ids="29785">nitro</z:chebi>-1,2,3,4-tetrahydro-1-quinoxalinyl]<z:chebi fb="22" ids="15366">acetic acid</z:chebi> monohydrate), a novel alpha-amino-3-hydroxy-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-<z:chebi fb="0" ids="35595">isoxazole</z:chebi> <z:chebi fb="0" ids="17272">propionate</z:chebi> (AMPA) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> with improved water solubility, was examined in a rat focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model </plain></SENT>
<SENT sid="1" pm="."><plain>Rats were subjected to permanent middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion using the intraluminal suture occlusion method for 24 h </plain></SENT>
<SENT sid="2" pm="."><plain>YM872 was intravenously infused for 4 h (20 and 40 mg/kg/h) or 24 h (10 and 20 mg/kg/h), starting 5 min after the <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, to investigate the effect of prolonged duration of the treatment on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="3" pm="."><plain>In the 4 h infusion study, YM872 reduced the cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 48% at a dose of 40 mg/kg/h </plain></SENT>
<SENT sid="4" pm="."><plain>YM872 did not significantly reduce the <z:mpath ids='MPATH_124'>infarct</z:mpath> at 20 mg/kg/h for 4 h </plain></SENT>
<SENT sid="5" pm="."><plain>In the 24 h infusion study, however, YM872 markedly reduced the cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 62%, even at 20 mg/kg/h </plain></SENT>
<SENT sid="6" pm="."><plain>The present study indicates that the neuroprotective effect of YM872 is enhanced by extending the duration of treatment, and demonstrates the benefit of the prolonged treatment with AMPA <z:chebi fb="68" ids="48706">antagonists</z:chebi> following focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>YM872, a highly water soluble compound, is applicable to investigate the role of AMPA receptors in ischemic models without concern about nephrotoxicity and could be useful in the treatment of human <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>